 | Up a level |
2020
Mayer-Hamblett, N., Van Koningsbruggen-Rietschel, S., Nichols, D. P., VanDevanter, D. R., Davies, J. C., Lee, T., Durmowicz, A. G., Ratjen, F., Konstan, M. W., Pearson, K., Bell, S. C., Clancy, J. P., Taylor-Cousar, J. L., De Boeck, K., Donaldson, S. H., Downey, D. G., Flume, P. A., Drevinek, P., Goss, C. H., Fajac, I, Magaret, A. S., Quon, B. S., Singleton, S. M., VanDalfsen, J. M. and Retsch-Bogart, G. Z. (2020). Building global development strategies for cf therapeutics during a transitional cftr modulator era. J. Cyst. Fibros, 19 (5). S. 677 - 688. AMSTERDAM: ELSEVIER. ISSN 1873-5010
2014
Rowe, S. M., McColley, S. A., Rietschel, E., Li, X., Bell, S. C., Konstan, M., Marigowda, G., Waltz, D. and Boyle, M. P. (2014). EFFECT OF 8 WEEKS OF LUMACAFTOR IN COMBINATION WITH IVACAFTOR IN PATIENTS WITH CF AND HETEROZYGOUS FOR THE F508DEL-CFTR MUTATION. Pediatr. Pulmonol., 49. S. 306 - 307. HOBOKEN: WILEY-BLACKWELL. ISSN 1099-0496